Navigation Links
Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
Date:1/30/2008

tential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines. The main adverse events associated with pixantrone in clinical trials to date include myelosuppression and alopecia.

About Brostallicin

Brostallicin, which was initially developed by Nerviano Medical Sciences, the largest pharmaceutical research and development facility in Italy, is a synthetic second-generation DNA minor groove binder with potent cancer killing activity in experimental tumors models. More than 200 patients have been treated with brostallicin in single-agent and combination studies, and it is now in a first-line phase II study that is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the marketing and development of ZEVALIN, or the development of XYOTAX, pixantrone and brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with ZEVALIN, XYOTAX, pixantrone and brostallicin in particular including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma, determinations by regulatory, patent and administrative governmental authoritie
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. Announces $6.5 Million Offering
4. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
5. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
6. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
9. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
10. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Chesapeake Regional Medical Center is the ... acquire Intuitive Surgical, Inc.’s latest model of the ... enhanced surgical technique capabilities, which can be used ... spectrum of specialties. Its advancements allow patients less ... times. , “As the only independent, community-based hospital ...
(Date:5/6/2015)... May 06, 2015 The Beryl Institute ... of Patient Experience Journal (PXJ), an international, open ... around understanding and improving patient experience. The second volume ... experience conversation globally, helps align the voices engaged and ... , Published in association with The Beryl Institute, Volume ...
(Date:5/6/2015)... 06, 2015 Is Colorado’s legal cannabis ... month the Centennial State will mark the 18-month milestone ... to adults. And while Colorado’s legal marijuana industry has ... time, it’s also facing some new challenges. , For ... facing shortages, especially in the wake of last month’s ...
(Date:5/6/2015)... vcfo, a specialized consulting firm that provides ... to optimize business performance and productivity, announced the additions ... Scheaffer. Both Lynch and Scheaffer have more than 25 ... “We are delighted to add Jack and Mike to ... background in financial management and leadership, Mike and Jack ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
Breaking Medicine News(10 mins):Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... is so much alike the code of humans, almost a ... And yet, // there are glaring differences, despite the 98% ... not a different set of genes that caused the difference, ... According to a latest theory on evolution, even small alterations ...
... many are not aware of the Medicare part D program’s guidelines. ... Roxbury Presbyterian Church was a great relief for them. ... the bus, which has been traversing New England cities and towns ... , The deadline to sign up for new prescription drug coverage ...
... Women with disproportionate or uneven breasts have a greater likelihood ... record any alterations or changes in the breast, the study ... conducted a study where mammograms of 252 women who developed ... healthy women. It was observed that, though breast cancer ...
... psychiatrist Dr Charles Reynolds at the University of Pittsburgh which ... , The study’s main aim was to analyze the ... people. It is one of the longest studies ever ... antidepressants for longer periods, perhaps even for life, in patients ...
... nominated to run the U.S. Food and Drug Administration, ... pressure while scientific decisions were being made//. He further ... medical endeavors, the appropriateness should also be taken into ... the FDA and Director of National Cancer Institute, would ...
... years old and two adults were placed under quarantine in ... part of Maharashtra. ,Tina Nanavade from Rawer taluka, ... was admitted to Nhavi Hospital on Sunday afternoon. Tami flu ... a possible bird-flu. ,Sarla More from Jamner, a ...
Cached Medicine News:Health News:Drugs Are Effective In Treating Depression and Preventing Recurrence 2Health News:FDA Nominee Says That He Is Not Influenced By Politics 2
(Date:5/6/2015)... , May 6, 2015  Rigrodsky & Long, P.A.: ... Inc. (NASDAQ GM: AERI )? , Did you purchase ... , Did you lose money in your investment in Aerie ... Rigrodsky & Long, P.A. , including ... announces that a complaint has been filed in the United States ...
(Date:5/6/2015)... South Africa , May 6, 2015 ... than HIV/AIDS, malaria and tuberculosis combined[1]. Approximately 40 percent of ... cured with the right treatment[3]. Together with Elekta, ministries of ... build up their radiation therapy infrastructures and save lives. ... would benefit from radiation therapy[4] during the course of their ...
(Date:5/6/2015)... Markets ( http://www.researchandmarkets.com/research/jskhnb/energy_based ) has announced the addition ... Business Report" report to their offering. The ... Canada , Japan , ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. The global market is ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 3Elekta to bring cancer treatment to millions in Africa 2Elekta to bring cancer treatment to millions in Africa 3Elekta to bring cancer treatment to millions in Africa 4Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 3
... volume laboratories, as well as specialty labs, ... simplicity and flexibility needed to respond to ... Elecsys 1010 system enables operators to handle ... testing without sacrificing ease of operation or ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... System provides high-performance detection technologies to ... and therapeutic drugs. It also delivers ... that allow the laboratory to streamline ... This high-productivity design enables numerous functions ...
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca...
Medicine Products: